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There is still a need for new agents which improve upon the therapeutic index of tiotropium,
the current standard of care for many patients with chronic obstructive pulmonary disease
(COPD). We examined in patients with COPD the efficacy of single doses of AZD9164, an M3-
selective muscarinic antagonist, to identify an appropriate dose-range for future studies.
COPD patients (n Z 28) inhaled AZD9164 (100, 400 and 1200 mg), tiotropium (18 mg) and
placebo at 5 study centre visits (Clinicaltrials.gov identifier NCT00939211). The effects of
these test drugs on average (Eav), peak (Emax) and trough (E22e26) forced expiratory volume
in one second (FEV1) were assessed, as were systemically-mediated effects and the safety
and exposure of single doses of AZD9164.
AZD9164 100, 400 and 1200 mg caused increases in FEV1 to peak effects of 12, 17 and 12%
above baseline respectively, following an initial transient and dose-related fall in FEV1 and
associated increase in mild respiratory symptoms such as cough. Bronchodilation was main-
tained overnight, with minimal FEV1 decline. AZD9164 400 and 1200 mg produced larger effects
than tiotropium on E22e26 (p < 0.05; both doses) while AZD9164 400 mg also had larger effects
on Emax (pZ 0.001) and Eav (p < 0.05). There were no serious adverse events and statistically
significant systemic effects were observed only with AZD9164 1200 mg.
AZD9164 may improve upon the therapeutic index of tiotropium, increasing the magnitude
and duration of lung function improvements without increasing systemically-mediated adverse
events. The initial bronchoconstrictor effect of AZD9164 requires further investigation.
ª 2012 Elsevier Ltd. All rights reserved.0 212 6845; fax: þ46 46 146793.
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Current guidelines for the treatment of chronic obstructive
pulmonary disease (COPD) recommend the use of long-
acting bronchodilators in patients who remain symptomatic
with short-acting bronchodilators.1 Tiotropium is the only
inhaled long-acting muscarinic receptor antagonist
currently available and has become the standard of care for
many patients with COPD, being both well tolerated and
efficacious at the recommended dose.1,2
Anticholinergic medications cause bronchodilation
primarily by blocking muscarinic (M) 3 receptors. These
receptors mediate bronchoconstriction via vagally derived
acetylcholine on airway smooth muscle. M1 receptors
facilitate cholinergic transmission and thereby potentiate
the effects of vagal bronchoconstriction. Antagonism of M1
receptors should further increase the bronchodilator effect
of M3 antagonism.
2,3
M2 receptors at cholinergic nerve endings inhibit the
release of acetylcholine and act as inhibitory feedback
receptors.2 Antagonism of prejunctional M2 receptors
therefore results in increased acetylcholine release in
human airways which may overcome the blockade of M3
receptors in the muscle.2 However, M2 receptors are also
abundant on airway smooth muscle and contribute to
muscle contraction by limiting adrenergic relaxation
through inhibition of ß2-adrenergic receptor-mediated
increases in adenylate cyclase. Blocking of postjunctional
M2 receptors on airway smooth muscle may thus provide
potential additional bronchodilation by removing the
inhibitory effect they have on ß2-agonist-induced
relaxation.
The binding affinity of tiotropium and ipratropium has
been reported to be similar for M1, M2, and M3 receptors,
but tiotropium dissociates >100 times more slowly than
ipratropium from M1 and M3 receptors, whereas dissociation
from M2 receptors is more similar.
2,4 This suggests that
tiotropium has a kinetic selectivity for M1 and M3 receptors
over M2 receptors. This kinetic selectivity is believed to be
why tiotropium is a more effective and longer-acting
bronchodilator than non-selective antagonists such as
ipratropium.2,4
Studies have shown that there are important lung func-
tion benefits associated with tiotropium therapy that are
maintained over periods up to 4 years, along with
improvements in quality of life and a reduced risk of
exacerbations and hospitalisations.5e7 However, current
licenced use of tiotropium, like ipratropium, is limited by
potential adverse effects (e.g. dry mouth, cough) to dose
levels that are below the maximal bronchodilating dose in
man.8 Early studies of tiotropium via the Handihaler sug-
gested potential for greater bronchodilator efficacy at
doses higher than those currently approved and well
tolerated. Recent data with the Respimat device have also
highlighted potential increased cardiovascular safety
concerns that may be due to higher systemic exposure with
the new device and formulation.9
The desire to improve upon the therapeutic index of
tiotropium and ipratropium has led to the development of
new anticholinergic agents with differing pharmacokinetic
and pharmacological characteristics, with the aim ofmaximising efficacy and minimising potential adverse
effects. AZD9164 is the result of a collaboration between
AstraZeneca Discovery and Pulmagen Therapeutics Limited
(formerly Argenta Discovery Limited), and is a selective,
competitive antagonist at the human M3 receptor. AZD9164
has potential as an inhaled, once-daily, long-acting anti-
muscarinic bronchodilator.
The aim of the study was to examine the efficacy of
single doses of AZD9164 in COPD patients and to identify an
appropriate dose-range for future clinical studies. The
doses of AZD9164 in the present study were chosen based
on safety data from a single ascending dose (SAD) study in
healthy volunteers, and the potency of AZD9164 was
examined in terms of lung function and systemic effects in
relation to tiotropium.10,11
Methods
A total of 60 patients were enrolled in the study, of whom
28 were randomised to treatment after a rigorous screening
process to ensure both their safety and eligibility to
participate in the study. To be eligible for the study,
patients were required to have had a diagnosis of COPD
with a post-bronchodilator FEV1 between 40% and 80% of
predicted normal and a FEV1/FVC ratio less than 70%.
Patients were further required to demonstrate reversible
airway obstruction (i.e. >10% increase in FEV1, after
3  40 mg ipratropium [Atrovent]) on two separate occa-
sions. The study comprised nine clinic visits, Visit 1 was for
enrolment and to obtain informed consent, Visits 2 and 3
assessed ipratropium reversibility and COPD severity, Visits
4e8 were study drug treatment visits with Visit 9 for follow-
up (Fig 1). Informed consent was needed prior to Visits 2
and 3 in order to be able to withdraw bronchodilators prior
to these lung function tests. Long-acting b2-agonists and
muscarinic antagonists were not allowed before Visit 2 and
throughout the study. Short-acting b2-agonists were to be
withheld 6 h and muscarinic antagonists 8 h before study
drug intake, but were allowed between visits.
Treatments and study design
The trial was a double-blind, double-dummy, placebo-
controlled, randomised, multi-centre, 5-way cross-over,
single dose study carried out at four centres in Sweden.
Patients inhaled three different single doses of AZD9164
(100 mg, 400 mg and 1200 mg estimated lung deposited
doses) or saline placebo via a Spira Electro 2 Dosimeter jet
nebuliser, 1 dose of tiotropium (18 mg) or lactose placebo
from a Handihaler dry-powder inhaler at five separate
overnight visits. Irrespective of treatment, patients were
required to take 19 inhalations from the nebuliser. Based on
times of the PK sample taken immediately after end of
inhalation, the inhalation procedure could be estimated to
be 6e9 min long. In the morning of each treatment visit,
the patient inhaled in a double-dummy fashion; first from
the nebuliser and then from the HandiHaler. The placebo
and active capsules were loaded into the Handihaler by
a neutral observer to maintain double-blind status. Training
in use of nebuliser and Handihaler was given prior to
treatment at Visit 3. The single dose administrations were
Figure 1 Study flow chart. ICF, Informed Consent Form.
Table 1 Demographic and disease-related data at entry.
Patient characteristic n Z 28 (all)
Gender Male n Z 13,
female n Z 15
Age (years) 64.2 (51e71)
Race White
BMI (kg/m2) 25.7 (20e34)
Time since COPD
diagnosis (years)a
5.5 (1e20)
Time since COPD
symptoms (years)a
9 (2e20)
Smoking status Former n Z 15,
current n Z 13
Pack years (years) 35.1 (14e56)
Inhaled GCS No n Z 7, yes n Z 21
Daily dose of
inhaled GCS (mg)
588.6 (320e1000)
Long-acting b2-agonist No n Z 10, yes n Z 18
Long-acting muscarinic
antagonist
No n Z 14, yes n Z 14
Short-acting b2-agonist No n Z 17, yes n Z 11
Short-acting muscarinic
antagonist
No n Z 22, yes n Z 6
Post-bronchodilator FEV1,
% pred (Visit 2)
61.1 (41e80)
Post-bronchodilator
reversibility % (Visit 2)
20.9 (11e61)
Post-bronchodilator
reversibility % (Visit 3)
22.1 (10e50)
GCS, Glucocorticosteroids.
a Median.
86 L. Bjermer et al.separated by wash-out periods of 7e14 days (Fig. 1). The
first dose (Visit 4) was to be given between 7.00 and 9.00 in
the morning. The dosing at the following visits (Visits 5e8)
was to take place within 1 h of the time of the dosing at
Visit 4. Time of first inhalation was used to represent when
the dose was administered.
If required, Bricanyl Turbuhaler could be adminis-
tered to patients as rescue medication at 0.25 mg per
inhalation. All use was recorded on study case report forms
with time of administration and the number of doses given
on each occasion.
The primary objective of the study was to investigate
the pharmacodynamics of inhaled AZD9164 in comparison
to tiotropium and placebo, with FEV1 as the primary vari-
able for local pulmonary effects. FEV1 was assessed as the
average effect over 24 h (Eav Z AUC0e24/24 h), the peak
(maximum) effect over 24 h (Emax) and the trough effect
(E22e26), here assessed as the average effect over 22e26 h.
Variables for systemically mediated effects included heart
rate, heart rate corrected QT interval (QTc), pulse and
blood pressure. The secondary objectives of the study were
to examine the safety of single doses of AZD9164 and to
investigate drug exposure to AZD9164.
Blood samples to determine the plasma concentration of
AZD9164 were taken prior to the administration of each
drug dose, and then repeated up to 24 h after administra-
tion. The lower limit of AZD9164 quantification in plasma
was 0.01 nmol/l. The first blood sample for PK determina-
tions after inhalation was drawn as soon as possible after
the patient had inhaled the investigational product.
Further samples were taken at 15, 30, 60 and 90 min and 2,
4, 6, 8, 12 and 24 h post-dose.
Statistical methods
Computed pharmacodynamic parameters based on the
peak, trough and average effects of variables (FEV1, pulse,
blood pressure, heart rate and QTc) were compared
between the five treatments using analysis of variance
(ANOVA) models with fixed factors for treatment, period
and patient, and using the baseline of the day (the pre-dose
value; for FEV1 the geometric mean of the two pre-dose
values) as a covariate. Additive models were used for
measures of systemic effects, while FEV1 was analysed
using multiplicative models. Pharmacokinetic parameters
were calculated using standard non-compartmentalmethods. These included area under the plasma concen-
trationetime curve from time 0 to 24 h post-dose
(AUC0e24), the maximum plasma concentration measured
(Cmax) and the time taken to reach Cmax (tmax).Results
Baseline characteristics
The baseline characteristics of patients are outlined in
Table 1. All participants allocated to treatment were white
with 13 (46%) male patients. The average patient age was
AZD9164 versus tiotropium in the treatment of COPD 8764.2 years (range: 51e71), with an average body mass index
(BMI) of 25.7 kg/m2 (range 20e34 kg/m2). Participants were
either former (15 [54%]) or current smokers with a smoking
history of at least 10 pack years, and a median time since
COPD diagnosis of 6 years (range: 1e20). Inhaled cortico-
steroids were used by 21 (75%) patients prior to the start of
the study, with 18 (64%) patients using long-acting b2-
agonists and 14 (50%) patients using long-acting anticho-
linergics. The average post-bronchodilator FEV1 at Visit 2
was 61.1% predicted normal (range: 41e80). The average
reversibility (after 120 mg ipratropium) was 20.9% (range
11e61%) and 22.1% (range: 10e50%) at Visits 2 and 3,
respectively.
Pharmacokinetics
Due to the long half-life of AZD9164 (on average 123 h, as
determined by the SAD study in healthy volunteers), many
pre-dose plasma samples contained quantifiable concen-
trations of AZD9164 (all below levels considered thera-
peutic). This was not corrected for when computing
pharmacokinetic parameters, thus exposure after low dose
may have been slightly overestimated. The absorption rate
of inhaled single doses of AZD9164 was fast, with a median
tmax of between 15 and 60 min. Following the peak in
plasma concentration of AZD9164, levels of the study drug
declined in a multi-phasic manner over the 24-h test period
(Fig. 2). The systemic exposure of AZD9164 increased
slightly more than dose-proportionally in the range
100e1200 mg as nebulised solution.
Pharmacodynamics
Shortly after inhalation, patients given AZD9164 exhibited
a rapid, dose-dependent decrease in FEV1. At the 15-min
post-dose time point, mean decreases in FEV1 of 3, 11
and 15% were observed for AZD9164 100 mg, 400 mg and
1200 mg respectively. This is in contrast to patients’
response to administration of placebo and tiotropium 18 mg,
which resulted in mean increases of 2% and 7% in FEV1
respectively (Table 2, Fig. 3).
A diurnal variation in FEV1 was seen after placebo admin-
istration, with a 3e5% increase during the day time, followed
by a decrease to baseline overnight before an increase in FEV1Figure 2 Mean plasma concentration curves on semi-
logarithmic scale.the following morning (Fig. 4). After tiotropium 18 mg, FEV1
peaked after 1 h, remained stable during the day time
(approximately 1e14 h post-dose), then declined during the
night (approximately 14e22 h post-dose). The initial decrease
in FEV1with AZD9164 100 mg andAZD9164 400 mgwas followed
by a rapid increase to reach peak effects of 12% and 17%
respectively at 2e6 h post-dose; effects which were main-
tained for 22e26 h post-dose. After the decrease in FEV1
following administration of AZD9164 1200 mg, it took
approximately 2 h for FEV1 to reach levels comparable
with the placebo group. FEV1 then increased by approxi-
mately 12% above baseline, with a minimal decline in FEV1
overnight.
At each of the three study doses, AZD9164 was associ-
ated with statistically significant increases relative to
placebo for Eav, Emax and E22e26. These improvements were
not dose-dependent, with AZD9164 400 mg consistently
producing the largest effect. This was most likely due to the
large initial decrease and slow recovery seen after AZD9164
1200 mg administration.
Tiotropium 18 mg produced statistically significant differ-
ences to placebo for Eav and Emax, but not on E22e26. The two
higher doses of AZD9164 (400 mg and 1200 mg) produced
statistically significantly larger effects than tiotropium 18 mg
on E22e26 while AZD9164 400 mg, but not 1200 mg, also had
significantly larger effects on Emax and Eav (Fig. 5).
Rescue medication at clinical visits
In total, 10 patients were given 59 doses of rescue medi-
cation at 18 study treatment visits (Table 3). The use of
rescue medication was most frequently reported during
AZD9164 1200 mg treatment (8 out of 28 patients), with
medication required shortly after inhalation of the study
drug (within 30 min). In contrast, rescue treatment
following tiotropium 18 mg was not initiated until during the
night. The frequency of rescue treatment use was lowest
during placebo days (1 patient).
ECG variables, pulse and blood pressure
Dose-dependent effects in heart rate were seen after
AZD9164, with 1200 mg producing a statistically significant
increase (mean increase 4 bpm) for both Emax and Eav in
comparison to placebo, which caused a decrease. No other
statistically significant effects were seen for heart rate or for
QTc. The outcome for pulse following AZD9164 1200 mg closely
followed the results for heart rate, with a statistically signifi-
cant increase in pulse relative to placebo for bothEmax and Eav.
Thiswas concomitantwith a statistically significant increase in
systolic blood pressure (as determined by Emax), but with no
significant change indiastolic bloodpressure.Tiotropium18mg
had no significant effect on any of these parameters.
Safety evaluations
Extent of exposure and adverse events
Of the 28 patients randomised to treatment, there were no
fatal adverse events, no serious adverse events, no
Table 2 Summary of individual changes in FEV1 at 15 min.
Treatment Decrease (no. of patients) Increase (no. of patients) Missing (no. of patients) Mean change in FEV1 (%)
AZD9164 100 mg 15 13 0 3
AZD9164 400 mg 22 6 0 11
AZD9164 1200 mg 24 2 2 15
Tiotropium 18 mg 7 20 1 þ7
Placebo 14 14 0 þ2
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adverse event and no patient withdrawals. The highest
frequency of adverse events was reported following
AZD9164 1200 mg, both in terms of the number of patients
with an event and the total number of events. The most
frequently reported adverse effects were cough, throat
irritation and dyspnoea (Table 4), appearing shortly after
inhalation.
Clinical laboratory evaluation
No safety concerns were identified based on haematology
or clinical chemistry, with no clinically significant changes
in parameters from pre-drug administration to 24-h post-
drug administration with investigational products in
comparison to placebo. Measurement of urinalysis variables
(protein, glucose and haemoglobin) pre- and post-drug
administration demonstrated no clinically relevant
changes.Discussion
The present study demonstrated an increase in lung func-
tion (as measured by FEV1) with all doses of AZD9164
(100 mg, 400 mg and 1200 mg) in comparison with placebo,
following an initial bronchoconstrictor effect. Furthermore,
the effect of AZD9164 400 mg and 1200 mg at 24 h was
superior to that seen with tiotropium 18 mg e the current
gold standard long-acting bronchodilator in COPD treat-
ment. A low dose of AZD9164 (100 mg) appeared to give
approximately the same 24-h bronchodilatory effect as
tiotropium 18 mg, as determined by peak, trough and
average FEV1.Figure 3 Mean value graph of change in FEV1 during first 4 h,
by treatment.An unexpected finding of the study was an immediate
but transient dose-related fall in FEV1 with AZD9164 that
was not observed following tiotropium or placebo treat-
ments. This was accompanied by a dose-related increase in
adverse effects, including cough, throat irritation and
dyspnoea, and occasionally rescue medication needed to
be given shortly after inhalation (30 min). The necessity of
rescue medication was highest following inhalation of
AZD9164 1200 mg (8 out of 28 patients). However, on an
individual basis, there was no clear association between the
degree of fall in FEV1, the occurrence of adverse effects or
the need for rescue medication. The high incidence of
respiratory effects following AZD9164 1200 mg did not
appear to influence absorption from the lungs into the
systemic circulation.
The initial bronchoconstrictor effects of AZD9164 were
unexpected as no similar effects were observed when single
doses even higher than in present study (up to 1940 mg)
were administered to healthy volunteers in the previous
SAD safety study. However, it should be noted that FEV1
measurements were not taken until 1.5 h after drug inha-
lation in the safety study. As the effects of muscarinic
antagonism vary with age and severity of inflammation,3 it
is possible that patients with COPD may respond differently
to inhalation of AZD9164 compared to healthy volunteers.
An additional, non-pharmacological possibility is that local
irritancy of AZD9164 may be greater in patients with COPD
than in healthy patients.
Another unexpected finding was the lack of a clear
doseeresponse to AZD9164 on FEV1, with the 400 mg dose
producing the largest effects. The doseeresponse and the
extent of bronchodilation at later time points may have
been affected by the magnitude of the initial drop in FEV1,Figure 4 Mean value graphs of change from baseline in FEV1
by treatment over 24e26 h.
Figure 5 Adjusted mean FEV1 ratios versus placebo with 95% confidence intervals. Treatment effects (differences versus
placebo) are expressed as (baseline-adjusted) ratios of active treatment over placebo.
Table 3 Patients using rescue medication at clinic visits.
Treatment n Users Doses
AZD9164 100 mg 28 3 8
AZD9164 400 mg 28 2 8
AZD9164 1200 mg 28 8 34
Tiotropium 18 mg 28 4 7
Placebo 28 1 2
AZD9164 versus tiotropium in the treatment of COPD 89particularly with the highest dose. It is not possible,
therefore, to draw conclusions over the full dose-range at
present.
Although an initial dip in FEV1 following AZD9164 was
observed, the subsequent bronchodilation was both
profound and prolonged. Bronchodilation at 22e26 h was
found to be significantly greater with AZD9164 than with
tiotropium 18 mg. This increased bronchodilation at 22e26 h
could be beneficial in combating the circadian drop in lung
function overnight if replicated in other patients.Table 4 Most frequent (> 5%) adverse events by preferred
term.
Preferred term A 100
mg
A 400
mg
A 1200
mg
T 18
mg
Placebo
Cough 0 6 (21%) 18 (64%) 1 (4%) 0
Throat
irritation
0 5 (18%) 8 (29%) 0 0
Dyspnoea 1 (4%) 2 (7%) 7 (25%) 0 0
Headache 1 (4%) 3 (11%) 2 (7%) 1 (4%) 1 (4%)
Nasopharyngitis 2 (7%) 3 (11%) 0 0 2 (7%)
Chest discomfort 0 2 (7%) 4 (14%) 0 0
Thrombophlebitis 0 2 (7%) 1 (4%) 0 0
Chronic
obstructive
pulmonary
disease
0 0 2 (7%) 0 0
Tremor 0 0 2 (7%) 0 0
n Z 28 for all treatment groups. A, AZD9164; T, tiotropium.If administration of AZD9164 resulted in either a brief
initial partial M1 agonist effect or an initial M2 antagonist
effect like that of ipratropium, before the expected pro-
longed blockade of M3 receptors, this would provide
a possible explanation for the brief, transient broncho-
constriction followed by prolonged bronchodilation
observed in this study. A further possibility is a brief partial
agonist effect on the M3 receptor. However, none of these
effects has been demonstrated in the laboratory or in pre-
clinical studies with AZD9164. Further research will be
required to investigate the dual drug response.
Even though a small initial bronchoconstriction was
observed immediately after inhalation of AZD9164, no
serious adverse events or systemic side effects (increases in
heart rate, pulse and systolic blood pressure) were
observed at the moderate doses, and could be detected
only at the highest dose. Indeed, it is possible that different
formulations of the AZD9164 molecule for inhalation could
result in even better safety profiles.
Conclusions
This study demonstrates that it is possible to increase both
the magnitude and duration of the improvements in lung
function resulting from the administration of an inhaled
muscarinic antagonist in patients with COPD. Tiotropium,
still the only long-acting muscarinic antagonist currently
available, is only approved at a dose of 18 mg via the
Handihaler and the potential to improve its bronchodila-
tory effects by administering higher doses may be
restricted by an accompanying increase in anticholinergic
effects, such as dry mouth. The present study with AZD9164
shows that it may be possible to improve on the broncho-
dilatory effects of tiotropium without an inevitable
increase in such effects. However, the observed initial
bronchoconstriction of AZD9164 would be deemed unac-
ceptable, and needs further investigation prior to any
larger clinical studies.
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